Gerard Sanacora

Yale University, New Haven, CT 
"Gerard Sanacora"
Cross-listing: Neurotree


Sign in to add mentor
John H. Krystal post-doc 1996-1999 Yale (Neurotree)


Sign in to add collaborator
Yann Mineur collaborator 2005- Yale (Neurotree)
Christopher J. Pittenger collaborator 2006- Yale (Neurotree)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Holmes SE, Finnema SJ, Naganawa M, et al. (2022) Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry
Averill LA, Averill CL, Gueorguieva R, et al. (2022) mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders
McIntyre RS, Rosenblat JD, Nemeroff CB, et al. (2021) Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American Journal of Psychiatry. appiajp202020081251
Pizzagalli DA, Smoski M, Ang YS, et al. (2020) Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Pothula S, Kato T, Liu RJ, et al. (2020) Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry
Averill LA, Abdallah CG, Fenton LR, et al. (2020) Early life stress and glutamate neurotransmission in major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Fu DJ, Ionescu DF, Li X, et al. (2020) Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). The Journal of Clinical Psychiatry. 81
Freeman MP, Hock RS, Papakostas GI, et al. (2020) Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology. 40: 287-292
Wajs E, Aluisio L, Holder R, et al. (2020) Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of Clinical Psychiatry. 81
Krystal AD, Pizzagalli DA, Smoski M, et al. (2020) A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine
See more...